Resistance to apoptosis should not be taken as a hallmark of cancer

Chinese Journal of Cancer

Volumn 33, Issue 2, 2014, Pages 47-50

  Wang, Rui An ^a   Li, Zeng Shan ^a   Yan, Qing Guo ^a   Bian, Xiu Wu ^b   Ding, Yan Qing ^c   Du, Xiang ^d   Sun, Bao Cun ^e   Sun, Yun Tian ^f   Zhang, Xiang Hong ^g  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c Nanfang Medical University   (China)

^d FudanUniversity ^*  (China)

^e TIANJIN MEDICAL UNIVERSITY   (China)

^f Chinese Research Academy of Environmental Sciences   (China)

^g HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Bcl 2; Cancer; Hallmark

Indexed keywords

CASPASE 3; CYCLIN D1; FAS ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER PROGNOSIS; CARCINOGENESIS; CELL PROLIFERATION; HEMATOLOGIC MALIGNANCY; HUMAN; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; TUMOR GROWTH;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOGENESIS; CASPASE 3; HUMANS; LYMPHOMA, B-CELL; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84893486564     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.013.10131     Document Type: Article

References (31)

1. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer, 1972,26:239-257.
2. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood, 1992,80:879-886.
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell, 2000,100:57-70.
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell, 2011,144:646-674.
5. Green DR, Evan GI. A matter of life and death. Cancer Cell, 2002,1:19-30.
6. Carrel A. Mechanism of formation and growth of malignant tumors. Ann Surg, 1925,82:1-13.
7. Fischer A. The theory of the developmental physiology of malignant tumors. 1937,31:1-20.
8. Lipponen PK, Aaltomaa S. Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. J Pathol, 1994,173:333-339.
9. Lipponen P, Aaltomaa S, Kosma VM, et al. Apoptosis in breast cancer as related to histopathological characteristics and prognosis. Eur J Cancer, 1994,30A:2068-2073.
10. Lipponen P. Apoptosis in breast cancer: relationship with other pathological parameters. Endocr Relat Cancer, 1999,6:13-16.
11. Krajewski S, Krajewska M, Turner BC, et al. Prognostic significance of apoptosis regulators in breast cancer. Endocr Relat Cancer, 1999,6:29-40.
12. Nishimura R, Nagao K, Miyayama H, et al. Apoptosis in breast cancer and its relationship to clinicopathological characteristics and prognosis. J Surg Oncol, 1999,71:226-234.
13. Enderling H, Hahnfeldt P. Cancer stem cells in solid tumors: is "evading apoptosis" a hallmark of cancer? Prog Biophys Mol Biol, 2011,106:391-399.
14. Callagy GM, Pharoah PD, Pinder SE, et al. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res, 2006,12:2468-2475.
15. Callagy GM, Webber MJ, Pharoah PD, et al. Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer, 2008,8:153.
16. Sinicrope FA, Hart J, Michelassi F, et al. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res, 1995,1:1103-1110.
17. Tomita M, Matsuzaki Y, Edagawa M, et al. Prognostic significance of bcl-2 expression in resected pN2 non-small cell lung cancer. Eur J Surg Oncol, 2003,29:654-657.
18. Knowlton K, Mancini M, Creason S, et al. Bcl-2 slows in vitro breast cancer growth despite its antiapoptotic effect. J Surg Res, 1998,76:22-26.
19. Murphy KL, Kittrell FS, Gay JP, et al. Bcl-2 expression delays mammary tumor development in dimethylbenz(a)anthracenetreated transgenic mice. Oncogene, 1999,18:6597-6604.
20. Chaudhary KS, Abel PD, Lalani EN. Role of the Bcl-2 gene family in prostate cancer progression and its implications for therapeutic intervention. Environ Health Perspect, 1999,107 Suppl 1:49-57.
21. Droin N, Guery L, Benikhlef N, et al. Targeting apoptosis proteins in hematological malignancies. Cancer Lett, 2013,332:325-334.
22. Chen L, Park SM, Tumanov AV, et al. CD95 promotes tumour growth. Nature, 2010,465:492-496.
23. Macher-Goeppinger S, Bermejo JL, Wagener N, et al. Expression and prognostic relevance of the death receptor CD95 (Fas/APO1) in renal cell carcinomas. Cancer Lett, 2011,301:203-211.
24. Ugurel S, Rappl G, Tilgen W, et al. Increased soluble CD95 (sFas/ CD95) serum level correlates with poor prognosis in melanoma patients. Clin Cancer Res, 2001,7:1282-1286.
25. Huang Q, Li F, Liu X, et al. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med, 2011,17:860-866.
26. Yin C, Knudson CM, Korsmeyer SJ, et al. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature, 1997,385:637-640.
27. Knudson CM, Johnson GM, Lin Y, et al. Bax accelerates tumorigenesis in p53-deficient mice. Cancer Res, 2001, 61: 659-665.
28. Baserga R. The relationship of the cell cycle to tumor growth and control of cell division: a review. Cancer Res, 1965,25:581-595.
29. Wang RA, Yan QG. Molecular adaptation of cancer cells. In: Popescu LM, Hargens AR, Singal PK, eds. Adaptation biology and medicine, Vol. 7. New Delhi: Narosa Publishing House, 2013:131-138.
30. Ames BN. Prevention of mutation, cancer, and other age-associated diseases by optimizing micronutrient intake. J Nucleic Acids, 2010,2010:1-11.
31. Wang RA, Li QL, Li ZS, et al. Apoptosis drives cancer cells proliferate and metastasize. J Cell Mol Med, 2013,17:205-211.